TISIDB

Summary
Symbol	PLA2G5
Name	phospholipase A2, group V
Aliases	FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location	1p36-p34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted.
Domain	PF00068 Phospholipase A2
Function	PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. This isozyme hydrolyzes more efficiently L-alpha-1-palmitoyl-2-oleoyl phosphatidylcholine than L-alpha-1-palmitoyl-2-arachidonyl phosphatidylcholine, L-alpha-1-palmitoyl-2-arachidonyl phosphatidylethanolamine, or L-alpha-1-stearoyl-2-arachidonyl phosphatidylinositol. May be involved in the production of lung surfactant, the remodeling or regulation of cardiac muscle.

> Gene Ontology [ TOP ]
Biological Process	GO:0006575 cellular modified amino acid metabolic process GO:0006631 fatty acid metabolic process GO:0006633 fatty acid biosynthetic process GO:0006636 unsaturated fatty acid biosynthetic process GO:0006644 phospholipid metabolic process GO:0006650 glycerophospholipid metabolic process GO:0006654 phosphatidic acid biosynthetic process GO:0006658 phosphatidylserine metabolic process GO:0006663 platelet activating factor biosynthetic process GO:0006690 icosanoid metabolic process GO:0006691 leukotriene metabolic process GO:0006820 anion transport GO:0006869 lipid transport GO:0008654 phospholipid biosynthetic process GO:0010517 regulation of phospholipase activity GO:0010518 positive regulation of phospholipase activity GO:0010876 lipid localization GO:0014074 response to purine-containing compound GO:0015711 organic anion transport GO:0015718 monocarboxylic acid transport GO:0015908 fatty acid transport GO:0015909 long-chain fatty acid transport GO:0016042 lipid catabolic process GO:0016053 organic acid biosynthetic process GO:0019370 leukotriene biosynthetic process GO:0032309 icosanoid secretion GO:0033559 unsaturated fatty acid metabolic process GO:0036148 phosphatidylglycerol acyl-chain remodeling GO:0036149 phosphatidylinositol acyl-chain remodeling GO:0036150 phosphatidylserine acyl-chain remodeling GO:0036151 phosphatidylcholine acyl-chain remodeling GO:0036152 phosphatidylethanolamine acyl-chain remodeling GO:0043410 positive regulation of MAPK cascade GO:0044283 small molecule biosynthetic process GO:0045017 glycerolipid biosynthetic process GO:0046394 carboxylic acid biosynthetic process GO:0046456 icosanoid biosynthetic process GO:0046469 platelet activating factor metabolic process GO:0046470 phosphatidylcholine metabolic process GO:0046471 phosphatidylglycerol metabolic process GO:0046473 phosphatidic acid metabolic process GO:0046474 glycerophospholipid biosynthetic process GO:0046486 glycerolipid metabolic process GO:0046488 phosphatidylinositol metabolic process GO:0046683 response to organophosphorus GO:0046942 carboxylic acid transport GO:0050482 arachidonic acid secretion GO:0051591 response to cAMP GO:0060191 regulation of lipase activity GO:0060193 positive regulation of lipase activity GO:0070371 ERK1 and ERK2 cascade GO:0070372 regulation of ERK1 and ERK2 cascade GO:0070374 positive regulation of ERK1 and ERK2 cascade GO:0071715 icosanoid transport GO:0072330 monocarboxylic acid biosynthetic process GO:0097164 ammonium ion metabolic process GO:1903963 arachidonate transport
Molecular Function	GO:0004620 phospholipase activity GO:0004623 phospholipase A2 activity GO:0005539 glycosaminoglycan binding GO:0008201 heparin binding GO:0016298 lipase activity GO:0047498 calcium-dependent phospholipase A2 activity GO:0052689 carboxylic ester hydrolase activity GO:1901681 sulfur compound binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04014 Ras signaling pathway hsa04270 Vascular smooth muscle contraction hsa04972 Pancreatic secretion hsa04975 Fat digestion and absorption hsa00564 Glycerophospholipid metabolism hsa00565 Ether lipid metabolism hsa00590 Arachidonic acid metabolism hsa00591 Linoleic acid metabolism hsa00592 alpha-Linolenic acid metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-1482788: Acyl chain remodelling of PC R-HSA-1482839: Acyl chain remodelling of PE R-HSA-1482925: Acyl chain remodelling of PG R-HSA-1482922: Acyl chain remodelling of PI R-HSA-1482801: Acyl chain remodelling of PS R-HSA-1483206: Glycerophospholipid biosynthesis R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-1483257: Phospholipid metabolism R-HSA-1483166: Synthesis of PA

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04014 Ras signaling pathway
hsa04270 Vascular smooth muscle contraction
hsa04972 Pancreatic secretion
hsa04975 Fat digestion and absorption
hsa00564 Glycerophospholipid metabolism
hsa00565 Ether lipid metabolism
hsa00590 Arachidonic acid metabolism
hsa00591 Linoleic acid metabolism
hsa00592 alpha-Linolenic acid metabolism
hsa01100 Metabolic pathways

Reactome

R-HSA-1482788: Acyl chain remodelling of PC
R-HSA-1482839: Acyl chain remodelling of PE
R-HSA-1482925: Acyl chain remodelling of PG
R-HSA-1482922: Acyl chain remodelling of PI
R-HSA-1482801: Acyl chain remodelling of PS
R-HSA-1483206: Glycerophospholipid biosynthesis
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1483257: Phospholipid metabolism
R-HSA-1483166: Synthesis of PA

Summary
Symbol	PLA2G5
Name	phospholipase A2, group V
Aliases	FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location	1p36-p34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PLA2G5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	PLA2G5
Name	phospholipase A2, group V
Aliases	FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location	1p36-p34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PLA2G5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PLA2G5
Name	phospholipase A2, group V
Aliases	FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location	1p36-p34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PLA2G5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.094	0.768
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.515	0.324
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.224	0.62
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.902	0.211
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.327	0.766
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.612	0.245
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.781	0.182
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.264	0.144
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.266	0.774
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.823	0.341
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.377	0.23
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.687	0.0119

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PLA2G5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	PLA2G5
Name	phospholipase A2, group V
Aliases	FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location	1p36-p34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PLA2G5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PLA2G5
Name	phospholipase A2, group V
Aliases	FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location	1p36-p34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PLA2G5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PLA2G5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PLA2G5
Name	phospholipase A2, group V
Aliases	FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location	1p36-p34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PLA2G5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PLA2G5
Name	phospholipase A2, group V
Aliases	FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location	1p36-p34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PLA2G5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PLA2G5
Name	phospholipase A2, group V
Aliases	FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location	1p36-p34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PLA2G5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PLA2G5
Name	phospholipase A2, group V
Aliases	FRFB; GV-PLA2; PLA2-10; hVPLA(2); Ca2+-dependent phospholipase A2; phosphatidylcholine 2-acylhydrolase 5; Gr ......
Chromosomal Location	1p36-p34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PLA2G5 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PLA2G5